FDA awaits Actavis permanent injunction

The drug company Actavis, producer of the heart drug Digitek, agreed to close several plants in New Jersey and will not resume operations at these plants until U.S. standards for testing and manufacturing have been met by the FDA. According to Pharma Tech Live, the FDA has filed a consent degree, banning Actavis from distributing drugs in Totowa and Little Falls, N.J. The agreement also gives the FDA the right to close the plants if violations persist and to fine the company $15,000 a day afterward. The FDA filed an action against Actavis Dec. 23, which was signed by Actavis on

SOURCE: Righting Injustice › FDA awaits Actavis permanent injunction